These findings demonstrate that PASMC-derived ET-1 drives the development of PAH in fpnC326Yfl/fl SMMHC-CreERT2+ mice, and that antagonism of the ETA receptor can both prevent and reverse the development of PAH. Here, EDN1 is linked to pulmonary arterial hypertension.